I. To evaluate 2-hydroxyglutarate (2HG) 1H magnetic resonance spectroscopy (MRS) signal in patients with intracranial glioma and correlate with treatment response prior to beginning treatment and after cycles 2, 4 and 8 of therapy and at time of confirmed evidence of progression.